Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) A pharmaceutical composition comprising:

(a) solubilized (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) or a combination of solubilized (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and another HIV protease inhibiting compound, or pharmaceutically acceptable salts thereof, in an [the] amount of from about 1 [%] to about 50 [% by] weight % of the composition [of the total solution];

(b) a pharmaceutically acceptable organic solvent which comprises a medium and/or long chain fatty acid or a mixture thereof in an [the] amount of from about 40 [%] to about 75 [% by] weight % of the composition [of the total solution], and ethanol or propylene glycol in an [the] amount of from about 1 [%] to about 15 [% by] weight % of the composition [of the total solution];

(c) water in an [the] amount of from about 0.4 [%] to about 3.5 [% by] weight % of the composition [of the total solution]; and

(d) optionally, a pharmaceutically acceptable surfactant.

2. (canceled) The composition according to claim 1 wherein said HIV protease inhibiting compound is (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir).

3. (previously presented) The composition according to claim 1 comprising a combination of ritonavir and and (2S, 3S, 5S) –2- (2,6-dimethylphenoxyacteyl)-amino-3-hydroxy-5-(2S-(1-tetrahydropyrimid-2-only)-3-methyl-butanoyl)amino-1,6-diphenylhexane.

4. (currently amended) The composition according to Claim 1 comprising ritonavir or a combination of ritonavir and another HIV protease inhibiting compound selected from the group consisting of:

(2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2S-(1-tetrahydropyrimid-2-onyl)-3-methyl-butanoyl)amino-1,6-diphenylhexane;

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir);

N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir);

5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;

1 -Naphthoxyacetyl-beta-methylthio-Ala-(2S, 3S)- 3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4-t-butylamide;

5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-butylamide;

[1S-[1R-(R-),2S*])-N[1] [3-[[[(1,1 -dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1 -(phenylmethyl)propyl]-2-[(2quinolinylcarbonyl)amino]-butanediamide;



;


O
HO
N
N
OH
HO
OH

;


O
N
N
H2N
NH2
HO
OH

;


H
OH
H
HO
H
N
N
O
PhS
O
N
H

[nelfinavir];


OH
OH
BocHN
H
N
NHBoc
Ph
O
O
N
O

;



;



; and



[tipranavir] ;

or a pharmaceutically acceptable salt thereof.

5. (previously presented) The composition according to claim 1 wherein said fatty acid is oleic acid.

6. (previously presented) The composition according to claim 1 wherein said surfactant is Polyoxyl 35 castor oil.

7. (original) The composition according to claim 1 wherein the solution is encapsulated into a hard gelatin capsule or a soft gelatin capsule.

8. (currently amended) The composition of Claim 1 wherein the solvent comprises (1) a pharmaceutically acceptable long chain fatty acid in an [the] amount of from about 40 [%] to about 75 weight % of the composition [by weight of the total solution]; (2) ethanol or propylene glycol in an [the] amount of from about 3 [%] to about 12 weight % of the composition [by weight of the total solution]; and (3) water in an [the] amount of from about 0.4 [%] to about 1.5 weight % of the composition [by weight of the total solution].

9. (currently amended) The composition of Claim 1 wherein the solvent comprises (1) oleic acid in an [the] amount of from about 40 [%] to about 75 weight % of the composition [by weight of the total solution]; (2) ethanol or propylene glycol in an [the] amount of from about 3 [%] to about 12 weight % of the composition [by weight of the total solution]; and (3) water in an [the] amount of from about 0.4 [%] to about 1.5 weight % of the composition [by weight of the total solution].

10. (currently amended) The composition of Claim 9 comprising ritonavir or a combination of ritonavir and another HIV protease inhibiting compound selected from the group consisting of:

(2S, 3S, 5S)-2-(2,6Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl]-amino-1,6-diphenylhexane;

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir);

N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir);

5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;

1 -Naphthoxyacetyl-beta-methylthio-Ala-(2S, 3S)- 3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4-t-butylamide;

5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-butylamide;

[[1S-[1R-(R-),2S*])-N[1] [3-[[[(1,1 -dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1 -(phenylmethyl)propyl]-2-[(2quinolinylcarbonyl)amino]-butanediamide;]

[1S-[1R-(R-),2S*]]-N[1] [3-[[[(1,1 -dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1 -(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide;



;



;


O
N
N
H_2N
NH_2
HO
OH

;


H
OH
H
H
N
N
HO
O
PhS
O
N
H

[nelfinavir];


OH
OH
BocHN
H
N
NHBoc
Ph
O
O
N
O

;


O
OH
H
N
H
N
H
N
N
H
N
O
O
Ph

;



; and



[tipranavir] ;

or a pharmaceutically acceptable salt thereof.

11. (currently amended) The composition of Claim 9 comprising (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) or a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and another HIV protease inhibiting compound selected from the group consisting of:

(2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl) amino-3-hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl-butanoyl)- amino-1,6-diphenylhexane,

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir),

N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir),



(nelfinavir),



and



(tipranavir);

or a pharmaceutically acceptable salt thereof.

12. (original) The composition of claim 1 wherein the HIV protease inhibiting compound is ritonavir or a combination of ritonavir and another protease inhibiting compound.

13. (original) The composition of claim 12 wherein the solution is encapsulated in a soft elastic gelatin capsule (SEC).

14. (currently amended) The composition of Claim 1 which comprises:

(a) solubilized (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) in an [the] amount of from about 1 [%] to about 30 weight % of the composition [by weight of the total solution];

(b) a pharmaceutically acceptable organic solvent which comprises (1) [(i)] oleic acid in an [the] amount of from about 30 [%] to about 75 weight % of the composition [by weight of the total solution] and (2) ethanol in an [the] amount of from about 3 [%] to about 12 weight % of the composition [by weight of the total solution]; and

(c) water in an [the] amount of from about 0.4 [%] to about 3.5 weight % of the composition [by weight of the total solution]; and

(d) polyoxyl 35 castor oil in an [the] amount of from about 0 [%] to about 20 weight % of the composition [by weight of the total solution].

15. (currently amended) A pharmaceutical composition comprising:

(a) (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) in an [the] amount of about 10 weight % of the composition [by weight of the total solution,] ;

(b) a pharmaceutically acceptable organic solvent which comprises (1) oleic acid in an [the] amount of from about 70 [%] to about 75 weight % of the composition [by weight of the total solution]; and (2) ethanol in an [the] amount of from about 3 [%] to about 12 weight % of the composition [by weight of the total solution];

(c) water in an [the] amount of from about 0.4 [%] to about 1.5 weight % of the composition [by weight of the total solution]; and

(d) polyoxyl 35 castor oil in an [the] amount of about 6 weight % of the composition [by weight of the total solution].

16. (original) The compositon of claim 15 wherein the solution is encapsulated in a soft elastic gelatin capsule (SEC).

17. (currently amended) The composition of Claim 1 which comprises:

(a) a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl) amino-3hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyI butanoyl)- amino-1,6--diphenylhexane in an [the] amount of from about 1 [%] to about 45 weight % of the composition [by weight of the total solution];

(b) a pharmaceutically acceptable organic solvent which comprises (1) [(i)] oleic acid in an [the] amount of from about 30 [%] to about 75 weight % of the composition [by weight of the total solution] and (2) propylene glycol in an [the] amount of from about 1 [%] to about 15 weight % of the composition [by weight of the total solution]; and

(c) water in an [the] amount of from about 0.4 [%] to about 3.5 weight % of the composition [by weight of the total solution].

18. (currently amended) The composition of Claim 17 which comprises:

(a) a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl) amino-3hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyI butanoyl) amino-1,6-diphenylhexane in an [the] amount of from about 1 [%] to about 45 weight % of the composition [by weight of the total solution,] ;

(b) a pharmaceutically acceptable organic solvent which comprises (1) oleic acid in an [the] amount of from about 70 [%] to about 75 weight % of the composition [by weight of the total solution]; and (2) propylene glycol in an [the] amount of from about 1 [%] about 8 weight % of the composition [by weight of the total solution];

(c) water in an [the] amount of from about 0.4 [%] to about 1.5 weight % of the composition [by weight of the total solution]; and

(d) polyoxyl 35 castor oil in an [the] amount of from about 2.5 [%] to about 10 weight % of the composition [by weight of the total solution].

19. (original) The composition of claim 18 wherein the solution is encapsulated in a soft elastic gelatin capsule (SEC).

20. (currently amended) A pharmaceutical composition comprising:

(a) a combination of solubilized (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) in an [the] amount of about 3.9 weight % of the composition [by weight of the total solution] and (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl) amino-3hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyI butanoyl) amino-1,6-diphenylhexane in an [the] amount of about 15.6 weight % of the composition [by weight of the total solution,] ;

(b) a pharmaceutically acceptable organic solvent which comprises (1) oleic acid in an [the] amount of about 70 weight % of the composition [by weight of the total solution]; and (2) propylene glycol in an [the] amount of about 7.5 weight % of the composition [by weight of the total solution];

(c) water in an [the] amount of about 0.5 weight % of the composition [by weight of the total solution]; and

(d) polyoxyl 35 castor oil in an [the] amount of about 2.5 weight % of the composition [by weight of the total solution].

21. (original) The composition of claim 20 wherein the solution is encapsulated in a soft elastic gelatin capsule (SEC).